Agenzia Italiana del Farmaco
Updated lists of allergens for specific immunotherapy and diagnosis published following the end of the transitional phase initiated with AIFA Decision DG 2130/2017 - Updated lists of allergens for specific immunotherapy and diagnosis published following the end of the transitional phase initiated with AIFA Decision DG 2130/2017
Updated lists of allergens for specific immunotherapy and diagnosis published following the end of the transitional phase initiated with AIFA Decision DG 2130/2017
Following a request from the companies concerned and, where relevant, after an evaluation by the Agency, the lists already published following the end of the transitional phase initiated with AIFA Decision DG 2130/2017 were updated on 10 December 2021. Specifically, the update concerns the lists of allergens for specific immunotherapy and diagnosis for which companies may continue the procedure for obtaining a marketing authorisation (Annex 1), for which the Agency has issued a refusal to continue the procedure (Annex 2) and for which companies have waived the procedure for obtaining a marketing authorisation (Annex 3).
Published on: 13 December 2021
🎥 Il Presidente #AIFA Robert Nisticò ospite di “Belli dentro, belli fuori”, il programma di @la7_tv...
Vai al post →
💗💚 💙 Oltre 2 milioni di persone in Italia convivono con una malattia rara.
La rarità non può sign...
Vai al post →
📢 Il CdA #AIFA approva la rimborsabilità di 6 nuovi medicinali:
✔️ 4 #farmaci per malattie rare, t...
Vai al post →
Dalla medicina “taglia unica” alle cure su misura
🧬 AIFA pubblica il Position Paper su medicina di ...
Vai al post →
📺 Domani in TV parliamo di #farmaci, #salute e #sicurezza
Il Presidente di #AIFA Robert Nisticò sar...
Vai al post →
📄 L'Agenzia Italiana del Farmaco e l'Organizzazione Nazionale Antidoping (NADO Italia) hanno siglat...
Vai al post →
